About Us
Empowering our visionary partners to design and optimise their gene therapies to make them as safe as possible.
About Us
Enabling the next generation of gene therapies
Safety of cell and gene therapies remains a major concern in the biopharmaceutical industry. Concinnity was formed out of the University of Edinburgh in 2023 to transform the safety of gene therapies by designing novel control mechanisms using its cutting-edge AI platform and synthetic biology expertise.
Our Team
Meet our expert team
Concinnity’s entrepreneurial team brings together a distinctive blend of experience in innovative AI and synthetic biology.
The company was co-founded by CEO, Jessica Birt and CSO, Dr Matthew Dale. The board is chaired by Professor David Venables, an experienced and successful entrepreneur in cell and gene therapy, CEO of Laverock Therapeutics and previously CEO of Synpromics. Additional scientific guidance is provided by the scientific advisory board, chaired by Professor Susan Rosser, an expert in synthetic biology and gene engineering.
Jessica Birt
CEO and Co-founder
Jessica’s background combines human health, computational biology and data science with a focus on the predicable design of biological systems.
Dr Matthew Dale
CSO and Co-founder
Matthew holds a PhD in Synthetic Biology and is committed to improving human health by driving innovation in biotechnology.
Realise a new era in gene therapy
Partner with Concinnity to enhance the safety and expand the applications of your gene therapies.